Abbvie has submitted its new JAK inhibitor, upadacitinib, to the FDA and EMA for consideration in moderate to severe rheumatoid arthritis https://t.co/49GspIEeYN
Links:
Jan-02-2019
Search for Terms or Answers
Search for Terms or Answers
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
